Post navigation

3 thoughts on “Midweek Biopharma Update – $BLRX $PATH $NEPT and others + Twitter bashers (Video)

  1. “anti business socialist” Exactly… ! Great video Scott!
    That being said, got a q for you: what’s the deal with Amicus? Do you think its a buy at sub 4’s? thanks, FDS

    1. I do think it’s a spec buy as I think the so called ” failed” 6 month 011 data was a control issue, possible concerning asymptomatic females. The company in their pr’s seems to hint they believe its a control issue as they have said ” we plan to seek approval” and not saying ” we will confer with GSK Am,how to proceed with Amigal.

Leave a Reply